BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu X, Sheng H, Wang L, Xia P, Wang Y, Yu L, Lv W, Hu J. A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients. Aging (Albany NY) 2021;13:10034-57. [PMID: 33795529 DOI: 10.18632/aging.202761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Luo P, Li S, Long X. N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy. Biochim Biophys Acta Rev Cancer 2023;1878:188873. [PMID: 36842764 DOI: 10.1016/j.bbcan.2023.188873] [Reference Citation Analysis]
2 Zhou K, Yang J, Li X, Xiong W, Zhang P, Zhang X. N7-Methylguanosine Regulatory Genes Profoundly Affect the Prognosis, Progression, and Antitumor Immune Response of Hepatocellular Carcinoma. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.893977] [Reference Citation Analysis]
3 Ma Y, Zhang H. Genomics and Prognosis Analysis of N6-Methyladenosine Regulators in Lung Adenocarcinoma. Front Genet 2021;12:746666. [PMID: 34956315 DOI: 10.3389/fgene.2021.746666] [Reference Citation Analysis]
4 Miao C, Fang X, Chen Y, Zhao Y, Guo Q. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis. Medicine (Baltimore) 2021;100:e27689. [PMID: 34889221 DOI: 10.1097/MD.0000000000027689] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zhan L, Zhang J, Zhu S, Liu X, Zhang J, Wang W, Fan Y, Sun S, Wei B, Cao Y. N6-Methyladenosine RNA Modification: An Emerging Immunotherapeutic Approach to Turning Up Cold Tumors. Front Cell Dev Biol 2021;9:736298. [PMID: 34616742 DOI: 10.3389/fcell.2021.736298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Quan C, Belaydi O, Hu J, Li H, Yu A, Liu P, Yi Z, Qiu D, Ren W, Ma H, Gong G, Ou Z, Chen M, Sun Y, Chen J, Zu X. N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target. Front Immunol 2021;12:697026. [PMID: 34526985 DOI: 10.3389/fimmu.2021.697026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]